Transgene’s Post

Since the 1950s, a chemotherapy drug known as 5-fluorouracil has been used to treat many types of cancer, including blood cancers and cancers of the digestive tract.Doctors have long believed that this drug works by damaging the building blocks of DNA. However, a new study from MIT has found that in cancers of the colon and other gastrointestinal cancers, it actually kills cells by interfering with RNA synthesis.The findings could have a significant effect on how doctors treat many cancer patients. Usually, 5-fluorouracil is given in combination with chemotherapy drugs that damage DNA, but the new study found that for colon cancer, this combination does not achieve the synergistic ...

It was a pleasure to share our most recent observations in the clinical trial with #ORCA-010 oncolytic adenovirus in newly diagnosed prostate cancer patients today at the annual conference of the #EACR 2024. In summary, our results shown demonstrate that injection of ORCA-010 in the prostate of these patients causes an expansion of proliferating and activated memory phenotype CD8+ T cells; a notable influx of CD8+ T cells into the prostate, where they accumulate in immune cell-rich “hot” areas and are actively cytotoxic; and an induction of systemic immune responses against prostate-associated antigens. Together, this suggests that ORCA-010 virus could be used to reduce recurrence after first line treatment of prostate cancer by stimulating immune responses against tumor cells.

New!🧐 Intravesical instillation-based mTOR-STAT3 dual targeting for #bladdercancer treatment ------ Recent intravesical administration of adenoviral vectors, either as a single injection or in combination with immune checkpoint inhibitors, exemplified by cretostimogene grenadenorepvec and nadofaragene firadenovec, has demonstrated remarkable efficacy in clinical trials for non-muscle invasive bladder cancer. The bi-specific siRNA strategy, encapsulated in an adenovirus, could be a promising tool to augment cancer treatment efficacy and overcome conventional therapy limitations associated with “undruggability.” Here Choi et al propose that dual targeting of mTOR and STAT3 is an advantageous strategy for intravesical therapy using adenoviruses. Full paper 🖥️ https://lnkd.in/dCxXY5Eq #Cancertherapy IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Our D001 Hereditary Cancer Panel 1 is even more complete! With the new version, you can now also detect the MSH2 exon 2-6 inversion. Would you like to try it? Contact us for a 40% discount* on all necessary reagents! D001 Hereditary Cancer Panel 1 targets the most common and relevant CNVs associated with 8 frequent hereditary cancers: breast, ovarian, colorectal, gastric, prostate, pancreatic, endometrial and melanoma. This assay detects CNVs in 28 genes with unparalleled certainty, even in complex regions (e.g. PMS2). In addition, it also targets 5 variants associated with a higher risk of developing hereditary cancer. More info and pricing of D001 Hereditary Cancer Panel 1 improved version here: https://lnkd.in/edPNE6U4 #mrcholland #digitalMLPA #hereditarycancer This product is for Research Use Only (RUO). Not for use in diagnostic procedures. *This offer is valid for first time users only. Other conditions may apply. 

Gallbladder cancer and Bile Duct cancer are rare and often go unnoticed until they’re in advanced stages. Screening for a cancer signal could lead to finding it earlier, when cancer is more treatable. #MultiCancerEarlyDetection #CancerScreening #GallbladderCancer #BileDuctCancer Important Safety Information: bit.ly/33m8pFa The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The overall sensitivity in study participants with gallbladder cancer was 70.6% (0% for stage I, 33.3% for stage lI, 75.0% stage IlI, 100% stage IV). Bile Duct Sensitivity 93.5%. References: 1. Key Statistics for Gallbladder Cancer. https://bit.ly/3Ts1pPw. https://bit.ly/3OBpSRV 2. Statistics About Bile Duct Cancer | Cholangiocarcinoma Stats. https://bit.ly/3Ts1pPw. https://bit.ly/3OtbWJN

📃Scientific paper: Cervical Lymphadenectomy in Papillary Thyroid Cancer Abstract: Papillary thyroid cancer (PTC) spreads preferentially to lymph nodes. When central or lateral cervical lymph node basins are macroscopically affected by PTC, compartmental clearance is the treatment of choice since this increases disease-free and arguably overall survival. The role of prophylactic central (pCND) and lateral node dissection (pLND) in the absence of macroscopic disease remains more contentious. A pCND at the index thyroidectomy may reduce the rate of locoregional recurrence and yield additional staging information that may direct adjuvant treatment. However, pCND is associated with morbidity, in particular hypoparathyroidism that probably exceeds any benefit that it may provide. This chapter reviews the current evidence for nodal dissection in differentiated thyroid cancer. Continued on ES/IODE ➡️ https://etcse.fr/RINpQ ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Cervical Lymphadenectomy in Papillary Thyroid Cancer Abstract: Papillary thyroid cancer (PTC) spreads preferentially to lymph nodes. When central or lateral cervical lymph node basins are macroscopically affected by PTC, compartmental clearance is the treatment of choice since this increases disease-free and arguably overall survival. The role of prophylactic central (pCND) and lateral node dissection (pLND) in the absence of macroscopic disease remains more contentious. A pCND at the index thyroidectomy may reduce the rate of locoregional recurrence and yield additional staging information that may direct adjuvant treatment. However, pCND is associated with morbidity, in particular hypoparathyroidism that probably exceeds any benefit that it may provide. This chapter reviews the current evidence for nodal dissection in differentiated thyroid cancer. Continued on ES/IODE ➡️ https://etcse.fr/RINpQ ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Certain tumor types, such as mismatch repair-proficient and microsatellite stable (pMMR/MSS) tumors, are linked to a poorer prognosis and limited response to Immune Checkpoint Inhibitors (ICI). These pMMR/MSS tumors present a hot-like phenotype, with high T cell infiltration and expansion, which is enhanced by ICI immunotherapy. The tumor immune microenvironment (TIME) is a key player in mediating tumor progression, dissemination, and ICI response. Omniscope analysis of peripheral blood samples from pMMR/MSS colorectal and endometrial cancer patients provides valuable insights into TIME composition, complexity, and expansion dynamics during ICI treatment. These insights shed light on immunotherapy-driven changes and potential mechanisms of resistance, offering deeper understanding of these challenging tumors. 🪧 https://lnkd.in/dKHUv6kZ #ScienceIsWeAll

📃Scientific paper: Absence of the Nonextension Sign as a Marker for Endoscopic Submucosal Dissection Suitability Abstract: Early gastric cancer is defined as gastric cancer confined to the mucosa or submucosa, irrespective of lymph node metastasis. Endoscopic submucosal dissection is a standard treatment of early gastric cancer. The nonextension sign consists of a protrusion of the surrounding mucosa into the lumen, resembling a trapezoidal shape. This phenomenon occurs when massive submucosal invasion by a cancer increases the thickness and rigidity of the gastric wall and may be useful to differentiate between mucosal or microinvasive submucosal and invasive submucosal cancers. Our case demonstrates the usefulness of the absence of the conventional endoscopic nonextension sign as a marker to decide the adequate approach for mucosal lesions. Continued on ES/IODE ➡️ https://etcse.fr/DNEbC ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

CAMBRIA-2 is for men or women who have ER-positive, HER2-negative early breast cancer that has an intermediate or high risk of coming back (recurrence). The aim of CAMBRIA-2 is to prevent breast cancer from coming back for patients with early-stage oestrogen receptor-positive, HER2-negative breast cancer, who have a medium to high risk of the cancer returning. CAMBRIA-2 will test if giving a new hormone therapy treatment known as a ‘Selective Estrogen Receptor Degrader’ (SERD) is better at stopping cancer from returning, compared to the usual hormone therapies, such as letrozole, anastrozole, exemestane, or tamoxifen. This research will also find out more about the side effects, safety and effectiveness of the SERD. For more information about the CAMBRIA-2 clinical trial visit: https://lnkd.in/gbGf6WkH